AGIO - Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress | Benzinga
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session –
– Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the
Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease –
– Agios to Webcast Virtual Investor Event on June 16, 2024, at 10 a.m. Eastern Time or 4 p.m. Central European Summer Time –
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that data from its programs will be presented at the European Hematology Association 2024 (EHA2024) Hybrid Congress, to be held June 13-16, 2024, in Madrid, Spain.
Data from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia will be presented in a plenary session on June 15, 14:45-15:15 CEST (Abstract #S104) and in a poster session on June 14, 18-19:00 CEST (Abstract #P1529). Additional presentations will highlight data across Agios' pipeline in rare blood disorders, including sickle cell disease and pyruvate kinase deficiency.
In total, seven abstracts led by Agios and external collaborators will be presented or published. The accepted abstracts are listed below and are available online on the EHA congress website at www.ehaweb.org.
Thalassemia
Data from the global Phase 3 ENERGIZE study of mitapivat in alpha- or beta- non-transfusion-dependent thalassemia.
Plenary Abstracts Session:
Title: ENERGIZE: A Global Phase 3 Study of Mitapivat Demonstrating Efficacy and Safety in Adults with Alpha- or Beta- Non-Transfusion-Dependent Thalassemia
Abstract: S104
Session Date and Time: Saturday, June 15, 14:45-15:15 CEST
Presenter: Ali T. Taher, M.D., Ph.D.; Naef K. Basile Cancer Institute, American University of Beirut Medical Center in Beirut, Lebanon
Poster Presentation:
Title: Improvements in Fatigue and 6-minute Walk Test in Adults with Alpha- and Beta-Non-Transfusion-Dependent Thalassemia: The Phase 3 ENERGIZE Trial of Mitapivat
Abstract: P1529
Session Date and Time: Friday, June 14, 18-19:00 CEST
Lead Author: Kevin H. M. Kuo, M.D., MSc, FRCPC; Division of Hematology, University of Toronto, Toronto, ON, Canada
Sickle Cell Disease
A look at the design of the Phase 3 portion of the RISE UP study, as well as information about Phase 2 open-label renal study.
e-Poster Presentations:
Title: Study Design of the Phase 3 Portion of RISE UP: A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Mitapivat in Patients with Sickle Cell Disease
Abstract: P2193
Time: Friday, June 14, 9:00 CEST
Lead Author: Biree Andemariam, M.D.; New England Sickle Cell Institute, University of Connecticut Health, Farmington, ...